Last checked at 
(Alliance News) - Angle PLC on Tuesday touted the publication of a study by researchers at the University of Tubingen in Germany, which showed that its Parsortix system outperformed the current laboratory standard for disseminated tumour cell harvest.
The Surrey, England-based medical diagnostics company announced the publication of a study looking at disseminated tumour cells in bone marrow from breast cancer patients, which was featured in the International Journal of Molecular Sciences.
Researchers at the University of Tubingen used Angle's Parsortix system for the isolation and harvest of DTCs from bone marrow samples in 360 breast cancer patients and compared results to the standard density centrifugation method for DTC detection.
The Parsortix system is Angle's patent protected circulating tumour cell harvesting technology, which enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.
The study found that the Parsortix system was easier to use and yielded significantly higher numbers of DTCs for further analysis, compared to the standard method for DTC detection.
The isolated DTCs were abundant and viable, which Angle said cannot be achieved with the standard method.
It argued that this provides more and new analysis options for DTC characterisation, including the assessment of biomarker status, which is important for targeted treatment selection and prognostic assessment.
"We are pleased to share the peer-reviewed publication by the University of Tubingen that demonstrates consistently high performance of the Parsortix system for the harvest of DTCs as opposed to CTCs. This is the second study centre to demonstrate successful enrichment and harvest of DTCs from bone marrow aspirate highlighting a range of additional potential uses of the Parsortix system in clinical practice," said Chief Scientific Officer Karen Miller.
Angle shares were trading 0.8% lower at 14.88 pence each in London on Tuesday afternoon.
By Holly Beveridge, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.